Your session is about to expire
What is Valproate Sodium
Valproic acidThe Generic name of this drug
Treatment SummaryValproic acid, also known as valproate, is a type of fatty acid derivative and anticonvulsant. It was originally developed in 1881 and used as an industrial and pharmaceutical solvent. In 1963, it was discovered to have anticonvulsant properties and was approved by the FDA in 1978 under the name Depakene. Valproic acid is used to treat epilepsy, mania, and migraines and is also being studied for its potential anti-cancer effects.
Depakeneis the brand name
Valproate Sodium Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Depakene
Valproic acid
1978
481
Effectiveness
How Valproate Sodium Affects PatientsValproate is used to reduce seizures and migraines, and it may also help control symptoms of bipolar disorder. Although the exact way it works isn't known, it is thought to act as an inhibitor in the brain and protect against nerve damage in these conditions. Valproate can also be toxic to the liver and harmful to unborn babies, though the reasons for this are unclear. Studies have suggested that it may help clear the human immunodeficiency virus (HIV) when taken with other medications, but this has not been proven. Taking Valproate also comes with a warning that it may cause HIV to become more active
How Valproate Sodium works in the bodyValproate works in multiple ways to help with epilepsy, migraines, and bipolar disorder. It increases the amount of an inhibitory neurotransmitter called GABA, which reduces nerve firing. Valproate also activates pathways related to brain growth and plasticity. Additionally, it reduces fatty acid production, lowering inflammation, and inhibits an enzyme that breaks down molecules which suppress tumors. Finally, Valproate increases the amount of acetylation on certain genes, which can help reduce symptoms of bipolar disorder.
When to interrupt dosage
The prescribed amount of Valproate Sodium is contingent upon the diagnosed issue, such as Seizures, Seizure, Absence and Complex Partial Seizures. The measure of dosage shifts as per the administration technique (e.g. Injection, solution - Intravenous or Capsule, delayed release) delineated in the table beneath.Condition
Dosage
Administration
Migraine
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Acute Coryza
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Behcet Syndrome
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Seizure, Absence
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Complex Partial Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Mental Depression
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Warnings
Valproate Sodium ContraindicationsCondition
Risk Level
Notes
POLG-related disorder
Do Not Combine
Significant hepatic impairment
Do Not Combine
Disease
Do Not Combine
Hepatic Disease
Do Not Combine
Enzymes
Do Not Combine
Common Valproate Sodium Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Valproic acid.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Valproic acid.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Valproic acid.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Valproic acid.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Valproic acid.
Valproate Sodium Toxicity & Overdose RiskValproate has an LD50 of 670 mg/kg when given orally to rats and 1098 mg/kg when given orally to mice. Symptoms of an overdose can include sleepiness, heart block, deep coma, and high sodium levels. In serious cases, death can occur, but patients have been known to recover from valproate concentrations as high as 2120 mcg/mL. Hemodialysis may be used to remove the drug from the bloodstream. Pregnant women are at an increased risk of having a baby with birth defects such as neural tube defects, clefts, and limb deformities. Valproate may
Valproate Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Valproate Sodium?
65 active trials are being conducted to evaluate the potential of Valproate Sodium in providing relief from Migraine, Complex Partial Seizures and Acute Coryza.Condition
Clinical Trials
Trial Phases
Seizures
0 Actively Recruiting
Seizure, Absence
0 Actively Recruiting
Behcet Syndrome
2 Actively Recruiting
Not Applicable
Mental Depression
3 Actively Recruiting
Not Applicable
Acute Coryza
1 Actively Recruiting
Not Applicable
Complex Partial Seizures
0 Actively Recruiting
Migraine
52 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Patient Q&A Section about valproate sodium
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is sodium valproate a mood stabilizer?
"Valproate is a mood stabilizer that reduces feelings of excitability, over-activity, and mood swings."
Answered by AI
What are the effects of sodium valproate?
"Valproate may cause nausea, upper abdominal cramps, abnormal liver function, weight gain, and diarrhoea. Neurological adverse effects such as tremor, fatigue, sedation, confusion, and dizziness are often observed."
Answered by AI
What is valproate sodium used for?
"Sodium valproate is a prescription medication used to treat epilepsy and bipolar disorder. It may also be used to prevent migraine headaches. The medication is available in capsules, tablets, and liquid form to be taken orally."
Answered by AI
Is sodium valproate a high risk drug?
"Valproate is a medication that is used to treat seizures. It is a type of anticonvulsant. The medication comes in many different forms, including tablets, liquids, and injection. It is also available as a generic medication."
Answered by AI